Mesoblast Limited vs Western Digital Corp — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while Western Digital Corp trades at $550.26 (market cap $168.00B). The key difference: Western Digital Corp is far larger — about 77.4× Mesoblast Limited's market cap, and Western Digital Corp pays a 0.12% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | WDC | |
|---|---|---|
Market Cap | $2.17B | $168.00B |
Sector | Technology | Technology |
52-Week High | $20.96 | $746.23 |
52-Week Low | $12.88 | $67.06 |
Enterprise Value | $2.17B | $166.35B |
Dividend Yield | — | 0.12% |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Western Digital (WDC) trades at $489.59, up 2.59% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish moving averages but positive analyst sentiment, including a $619.07 consensus price target representing 26% upside. Recent volatility reflects sector rotation in memory stocks amid AI infrastructure expansion driving storage demand.
WDC presents compelling growth potential from AI-driven storage demand but faces near-term volatility from competitive pressures and sector rotation. The company's improving profitability (55.07% net margin) and cash flow generation support the bullish analyst outlook, though investors should monitor execution against Q2 2026 earnings expectations of $3.34 EPS.
Trailing returns across standard periods
Latest headlines on both assets
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →